Table 2 Quality of life scales at baseline according to treatment assignment

From: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

Quality of life scales

Continuous letrozole (n = 455)

Intermittent letrozole (n = 500)

Continuous letrozole (n = 455)

Intermittent letrozole (n = 500)

 

Original score rangea

Transformed score rangeb

 

Mean

SD

Mean

SD

Mean

SD

Mean

SD

BCPT symptom scalesa

 Hot flushes

1.1

1.0

1.1

1.1

71.8

24.6

71.5

27.0

 Nausea

0.1

0.3

0.1

0.4

97.0

8.5

96.4

10.2

 Bladder control

0.5

0.8

0.5

0.7

86.8

19.0

86.5

18.1

 Vaginal problems

1.2

1.2

1.1

1.2

69.2

31.1

71.8

30.4

 Musculoskeletal pain

1.2

0.9

1.3

1.0

69.8

23.0

68.6

24.0

 Cognitive problems

1.0

0.9

1.0

0.9

74.3

21.6

75.1

22.5

 Weight problems

1.0

1.0

0.9

1.0

74.7

24.6

76.8

24.7

 Arm problems

0.6

0.8

0.6

0.8

85.6

19.5

85.1

19.9

LASA symptom scales

 Hot flushes

    

69.1

28.4

68.6

30.4

 Sleep disturbance

68.0

26.6

67.7

28.9

 Tiredness

62.6

27.6

63.7

26.4

 Difficulties in becoming aroused

64.2

30.1

66.7

29.7

 Loss of sexual interest

54.3

33.4

55.9

34.2

LASA global scales

 Physical well-being

78.2

20.7

77.6

22.2

 Mood

78.0

22.0

76.8

23.2

 Coping effort

79.0

23.6

76.8

81.3

 Treatment burden

77.5

23.5

77.4

23.4

  1. SD standard deviation
  2. aBCPT original scales (i.e., symptom dimensions obtained by the mean of the corresponding two or three items) range from 0 to 4
  3. bTransformed BCPT and LASA scales range from 0 to 100, with higher scores indicating a better condition